Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2008-07-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
NCT01767948
A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects
NCT07027982
A Two-part Pharmacokinetic Study of PXS-5382A in Healthy Adult Males
NCT04183517
Pharmacokinetic Study to Characterize Individual Metabolic Profile
NCT01188525
A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
NCT00759564
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Placebo
PCA
Placebo tablet, once
2
Slow release PCA derivative
PCA
PO, 700mg, once
3
Slow release PCA derivative higher dose
PCA
PO, 1000mg, once
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PCA
Placebo tablet, once
PCA
PO, 700mg, once
PCA
PO, 1000mg, once
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males
* Age 18-45 years
* Abstinence from alcohol for 1 week prior to the study
* Non smoking
* BMI \> 19 and \< 30
* No history or evidence of significant
* cardiovascular,
* hepatic,
* renal,
* hematopoietic,
* gastrointestinal disease,
* endocrine,
* metabolic,
* psychiatric
* psychological disorders
* Normal physical examination
* Within +/- 10% of normal values in laboratory examinations
Exclusion Criteria
* Subjects who smoke.
* Subjects who drink \> 20 grams of alcohol per day.
* Subjects who take prescription medication.
* Subjects with an abnormality in screening blood tests
* Known sensitivity to any ingredients in the study drug
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hadassah Medical Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hadassah Medical Organization
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah Medical Organization
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCA pharmacokinetics 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.